Fig. 7

Targeting Lkb1 expression on Tregs alleviates lymphoma tumor progression. A Schematic design of humanized DLBCL models. Tregs was transduced with Lkb1shRNA (ShLkb1) or non-silencing scrambled control (ShNC). NSG mice were injected with Treg cells (shLkb1, n = 5) or Treg cells (ShNC, n = 5) along with SU-DHL4 cells and CD8⁺CTLs through tail vein. B, C Representative examples and summary weight data of spleens derived from two groups of lymphoma mice (n = 5). D For survival analysis, NSG mice were monitored until ethical euthanasia according to signs of morbidity. Survival was plotted by using the Kaplan-Meier method. E, F NSG mice from ShLkb1 and ShNC group were euthanized to evaluate tumor burden at day 35. Representative flow cytometry plots and summary data of CD45-positive cells rates in liver and spleen (n = 4). G Representative Hematoxylin and eosin (H&E) images from two groups showing different infiltration levels of tumor in liver. H Immunofluorescence staining of CD20 B cells from different groups for CD20 (red) and DAPI (blue). *P < 0.05; **P < 0.01, ***P < 0.001. p values were determined by two-sided unpaired t-test; data are presented as mean values ± SEM